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Abstract
Introduction US claims data contain medical data on large heterogeneous populations and are excellent sources for medi-
cal research. Some claims data do not contain complete death records, limiting their use for mortality or mortality-related 
studies. A model to predict whether a patient died at the end of the follow-up time (referred to as the end of observation) is 
needed to enable mortality-related studies.
Objective The objective of this study was to develop a patient-level model to predict whether the end of observation was 
due to death in US claims data.
Methods We used a claims dataset with full death records,  Optum© De-Identified  Clinformatics® Data-Mart-Database—Date 
of Death mapped to the Observational Medical Outcome Partnership common data model, to develop a model that classi-
fies the end of observations into death or non-death. A regularized logistic regression was trained using 88,514 predictors 
(recorded within the prior 365 or 30 days) and externally validated by applying the model to three US claims datasets.
Results Approximately 25 in 1000 end of observations in Optum are due to death. The Discriminating End of observation into 
Alive and Dead (DEAD) model obtained an area under the receiver operating characteristic curve of 0.986. When defining 
death as a predicted risk of > 0.5, only 2% of the end of observations were predicted to be due to death and the model obtained 
a sensitivity of 62% and a positive predictive value of 74.8%. The external validation showed the model was transportable, 
with area under the receiver operating characteristic curves ranging between 0.951 and 0.995 across the US claims databases.
Conclusions US claims data often lack complete death records. The DEAD model can be used to impute death at various 
sensitivity, specificity, or positive predictive values depending on the use of the model. The DEAD model can be readily 
applied to any observational healthcare database mapped to the Observational Medical Outcome Partnership common data 
model and is available from https ://githu b.com/OHDSI /Study Proto colSa ndbox /tree/maste r/DeadM odel.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-019-00827 -0) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Large observational healthcare datasets can be utilized by 
epidemiologists to learn new insights about disease and the 
effects of medical interventions in a real-world setting where 
patient populations are more heterogeneous than in rand-
omized clinical trials [1]. They are essential for learning 
about rare or delayed outcomes [2]. Studies have shown that 
well-designed epidemiologic studies using observational 
data can yield similar results to randomized clinical trial 
data [3], the gold standard for epidemiological analysis. 
Administrative claims databases are particularly valuable for 
pharmacoepidemiologic research, as they commonly repre-
sent a closed population with a defined period of eligibility, 
during which time there is strong confidence in the capture 
of covered inpatient and outpatient medical services and 
outpatient pharmacy dispensing records, which allows for 
inferring associations between drug exposure and outcome 
incidence that can be defined by diagnostic or procedure 
codes. Unfortunately, one outcome of particular interest is 
not consistently available, which limits the utility of these 
data: mortality. End of observation, that is the time when 
a person is no longer followed in claims data can occur for 
multiple reasons, e.g., it was the cut-off calendar date for 
all patients in the database, the person changed insurance 
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Key Points 
Death can be incompletely recorded in US claims data 
and this can limit drug safety studies that use these 
datasets.
We present a model that can predict whether the end of 
observation was due to death in US claims data with a 
discriminative performance of 0.986 on the area under 
the receiver operating characteristic curve.
The model is available online and can be readily applied 
to any dataset in the Observational Medical Outcomes 
Partnership common data model.
available as an open source R package and implements a 
process for developing patient-level prediction models while 
addressing existing best practices towards ensuring models 
are clinically useful and transparent. The datasets used for 
development and validation are described below.
All the datasets were mapped to the Observational Medi-
cal Outcome Partnership common data model [9], as hav-
ing the datasets in a homogeneous data structure enables 
re-use of the code between model development and valida-
tion to ensure the model can be externally validated effi-
ciently and reduces model reproducibility errors. The use 
of IBM  MarketScan® and Optum databases was reviewed 
by the New England Institutional Review Board and was 
determined to be exempt from broad institutional review 
board approval. We share all the code required to perform 
the analysis in this article or apply the developed model on 
new data via online supplements or on github (https ://githu 
b.com/OHDSI /Study Proto colSa ndbox /tree/maste r/DeadM 
odel).
2.1  Development Dataset
The Optum© De-Identified  Clinformatics® Data Mart 
Database—Date of Death (Optum DOD)—Optum© 
 Clinformatics® Extended Data Mart (Eden Prairie, MN, 
USA) is an adjudicated US administrative health claims 
database for members of private health insurance. The data-
base contains insurance claims data (inpatient/outpatient 
medical conditions and drug dispensing plus some labo-
ratory data) for US patients aged between 0 and 90 years. 
In this dataset, each state had a mandatory requirement to 
report patient deaths up until 2013, after 2013, it was no 
longer mandatory and therefore death may not be complete 
from 2013 onwards. The DOD table is sourced from the 
Death Master File maintained by the Social Security Office. 
The DeathMaster data provide year and month of death 
only. The dataset contains 73,969,539 individuals with data 
recorded between 1 May, 2000 and 31 March, 2016.
2.2  Validation Datasets
The IBM  MarketScan® Medicare Supplemental Database 
(MDCR) represents health services of retirees in USA with 
primary or Medicare supplemental coverage through pri-
vately insured fee-for-service, point-of-service, or capitated 
health plans. These patients are aged 65 years or older and 
have additional private insurance and are thus likely to be 
more affluent than average. These data include adjudicated 
health insurance claims (e.g., inpatient, outpatient, and out-
patient pharmacy). The database contains 9,559,877 indi-
viduals with data recorded between 1 January, 2000 and 30 
April, 2016.
coverage, or the person died, but not all claims databases 
offer sufficient information to know the reason for each 
patient with complete confidence. The claims data used in 
this study do not provide reasons for the end of enrollment. 
When a patient is no longer observed, it could be because 
they discontinued/switched insurance or because he/she is 
deceased.
Many US insurance claims databases only have death at 
discharge recorded, thus people who die outside the hospital 
are unlikely to have their death recorded. If methods could 
be developed to impute death into claims data, then these 
large datasets could be used to generate additional evidence 
in mortality-related studies.
There are various comorbidity models that can be imple-
mented for claims data, with the most commonly used being 
the Charlson Comorbidity Index [4] and the Elixhauser 
Comorbidity Index [5]. These models have been shown to 
be predictive of mortality [6], even across non-US and non-
claims data [7]. However, these models are prognostic, thus 
they have not been developed to impute death, instead, they 
predict future mortality risk.
The  Optum© De-Identified  Clinformatics® Data Mart 
Database—Date of Death claims dataset has complete 
death records up to 2013. The objective of this study was to 
use this dataset to develop and validate a model to predict 
whether a patient’s end of observation is due to death. We 
then investigate whether the model can be used to impute 
death in other US claims datasets that lack complete death 
records.
2  Methods
We followed the Observational Healthcare and Data Science 
Informatics (OHDSI) Patient Level Prediction framework 
[8] to develop and validate the model. The framework is 
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The IBM  MarketScan® Multi-State Medicaid Database 
(MDCD) contains adjudicated US health insurance claims 
for Medicaid enrollees from multiple states and includes 
hospital discharge diagnoses, outpatient diagnoses and pro-
cedures, and outpatient pharmacy claims as well as ethnicity 
and Medicare eligibility. Patients in the MDCD have subsi-
dized health insurance and are aged less than 65 years. The 
database contains 21,577,517 individuals with data recorded 
between 1 January, 2006 and 31 December, 2014.
The IBM  MarketScan® Commercial Database (CCAE) 
represents data from individuals enrolled in US employer-
sponsored insurance health plans. The data include adju-
dicated health insurance claims (e.g., inpatient, outpatient, 
and outpatient pharmacy) as well as enrollment data from 
large employers and health plans who provide private health-
care coverage to employees, their spouses, and dependents. 
The patients in the CCAE are aged 65 years or younger. 
The database contains 131,533,722 individuals with data 
recorded between 1 January, 2000 and 30 April, 2016.
The Optum DOD development dataset contains complete 
death records (death at discharge and all other deaths) up 
to 2013 and contains older and younger patients. The IBM 
datasets used for validation only have death at discharge 
(when a patient dies in hospital) recorded. The validation 
datasets also tend to have limited patient age ranges (e.g., 
older than 65 years or younger than 65 years). The databases 
capture all inpatient and outpatient medical services and out-
patient pharmacy claims, which are submitted through the 
payer. This generally would include claims submitted and 
subsequently adjudicated to be reimbursed by a secondary 
payer as co-insurance. For example, the MDCR database 
includes claims from services reimbursed by national Medi-
care coverage in addition to the supplemental coverage.
2.3  Target Population
The target population for model development was defined 
as patients with an end of observation in Optum DOD data 
between 2011-01-01 or 2012-11-01 who had been in the 
database for at least 1 year prior to their end of the observa-
tion date. The target population index date was the end of the 
observation date (the date they left the database).
We chose to use the end of observation between 2011-
01-01 or 2012-11-01 as we investigated death up to 61 days 
afterwards and death records were complete in the Optum 
DOD during this period. Since 2013, the death records have 
become incomplete.
2.4  Outcome
A patient in the target population was classified as ‘dead’ 
if they had a death record within 61 days of the end of 
observation. To review the SQL code used to create the 
datasets, see Electronic Supplementary Material (ESM) 1.
2.5  Predictors
The model variables were constructed using the records on 
or prior to the target population index date. The variables 
included were:
• Age in 5-year groups (e.g., 0–5, 5–10).
• Sex.
• Month of target index.
• Conditions (singular and grouped using a vocabulary 
hierarchy) in prior 365 days and prior 30 days;
• Drugs (singular and grouped into ingredients) in prior 
365 days and prior 30 days.
• Procedures in prior 365 days and prior 30 days.
• Measurements in prior 365 days and prior 30 days.
• Observations in prior 365 days and prior 30 days.
• Healthcare utility in prior 365 days and prior 30 days.
Note, discharge status (which indicates patients who died 
while in the hospital) was not included as a predictor in the 
model. We chose to only use the records that occurred in 
the prior 365 days to allow for the death risk model to be 
readily applied to any other dataset with at least 1 year of 
observation.
2.6  Statistical Analysis Methods
The development dataset was split into a training set (75% 
of the data) and a testing set (25% of the data) to perform an 
internal validation of the model. The chosen classifier was a 
regularized logistic regression with lasso regularization [10] 
and the hyper-parameter controlling the amount of regulari-
zation was acquired using an adaptive search and three-fold 
cross validation on the train set.
To internally evaluate the model, the model discrimina-
tion on the test set was assessed using the area under the 
receiver operating characteristic curve (AUC) and the model 
calibration was assessed by inspecting a calibration plot gen-
erated by binning the patients into ten groups based on their 
predicted death risk and comparing the observed fraction of 
the group with a death record observed around the end of 
observation vs. the mean predicted death risk for the group. 
To investigate whether the model is reproducible or trans-
portable across US claims data, an external validation was 
implemented across three US claims datasets. However, in 
the other claims datasets, only death at discharge is recorded; 
therefore, to externally validate the model we applied it to 
a set of patients where the patients had a death at discharge 
recorded (only a subset of actual deaths) or had an end of 
observation followed by a future observation period (were 
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definitively alive). If a patient had a death at discharge 
recorded they were defined as dead. For more details see 
ESM 2.
3  Results
3.1  Data Summary
A random sample of 1,000,000 patients in Optum DOD with 
an observation period ending within 2011-01-01–2012-11-
01 was selected as the target population and for 24,531 of 
these patients, death was recorded within 61 days of the 
observation end date (2.45%). The median and mean time 
between the recorded death and the end of observation was 
0 and 3 days, respectively, and 91% of deaths were at the end 
of the observation date. The characteristics of the sampled 
target population for the demographics and key predictors 
of death are presented in Table 1.
Table 1 presents the baseline characteristics of the devel-
opment datasets and validation datasets. Illnesses that are 
the most associated with death included cardiac diagnoses, 
disorders related to old age, and neoplasms. The Charlson 
Comorbidity Index was on average 7 for those with a death 
around the end of the observation whereas it was 1 or less 
for people with an end of observation but no death recorded, 
except for the MDCR where it was 2, as the patients are 
older and sicker in that database. An extended version of 
Table 1 with more variables is available, see ESM 4.
3.2  Model Specification
The Discriminating End of observation into Alive and 
Dead (DEAD) model developed in Optum DOD with a 
target size of 1,000,000 and an outcome count of 24,531 
is described in ESM 5 and is available from https ://githu 
b.com/OHDSI /Study Proto colSa ndbox /tree/maste r/DeadM 
odel. The model can be interactively explored at http://data.
ohdsi .org/DeadI mputa tion/. Of 88,514 candidate predictors, 
2097 were selected into the final model. The trained model’s 
coefficient values are available, see ESM 5. Figure 1 is a 
visualization showing the differences between patients with 
an end of observation due to death and those without. It is 
a scatter plot with the mean value for each of the 88,514 
variables within patients whose end of observation is not 
due to death (x axis) and patients whose end of observation 
is due to death (y axis). Variables that do not discriminate 
whether an end of observation is due to death or not fall on 
the diagonal. Those that fall above the diagonal are more 
common in patients whose end of observation was due to 
death. Those that fall below the diagonal are less common in 
patients whose end of observation was due to death.
3.3  Model Performance
The internal validation of the DEAD model obtained an 
AUC of 0.986 on the test set (0.989 on the train set), the 
receiver operating characteristic curve plot is presented in 
Fig. 2. The calibration plot for the internal validation of the 
model is presented in Fig. 2.
The DEAD model can be used to identify patients with 
an end of observation likely to be due to death or patients 
with an end of observation unlikely to be due to death. The 
required sensitivity, specificity, and positive predictive value 
(PPV) of a model is often context dependent, thus we pre-
sent various predicted risk cut-offs in Tables 2 and 3. If a 
user wishes to find an end of observation due to death, then 
Table 2 should be used. If a study requires definitive deaths, 
the user may require a high specificity of 99.9%, thus he/she 
can go down the specificity of the death column to find the 
cell with 99.9 and then move to the prediction threshold col-
umn to find the cut-off value to use, 0.905 in this example. 
He/she would then select the end of observation with a risk 
of 0.905 or higher as being due to death, this would have a 
PPV of 87.2% but only have a sensitivity of 25.6%. If a user 
wished to find 50% of all deaths (50% sensitivity), then the 
prediction threshold corresponds to a cut-off of 0.66. This 
threshold suggests that classifying a risk ≥ 0.66 as being due 
to death would have a PPV of 79.5% and a specificity of 
99.7%. Alternatively, a user may wish to identify the end of 
observations that are unlikely to be due to death, thus he/she 
would use Table 3. If he/she wanted to find the end of obser-
vations that are not due to death with a specificity of 99.9%, 
then he/she would use Table 3 to scroll down the specificity 
of the alive column to the cell with 99.9, this would indi-
cate a prediction threshold of 0.00055 and then he/she could 
select the end of observations with a risk less than 0.00055 
and class these as not being due to death. This would result 
in a PPV of 99.993% and a sensitivity of 34.6% (i.e., would 
identify 34.6% of all end of observations not due to death).
The external validation on CCAE, MDCR, and MDCD 
returned AUCs of 0.995, 0.951, and 0.977, respectively. Full 
details for the external validation models and results, see 
the ESM 2.
Differences between the patients the model incorrectly, 
but confidently, predicted were dead compared to patients 
the model incorrectly predicted were alive can be seen in 
ESM 3. As expected, if a patient did not have obvious health 
issues, then the model struggled to predict the patient as 
dead, whereas if a patient had many serious comorbidities 
the model was likely to predict an end of observation as due 
to death.
Figure 3 shows the recorded deaths (death identified by 
model, death not identified by model) and imputed death 
(where the DEAD model predicted the risk of death ≥ 0.5 
but the patient did not have death recorded) for all end of 
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observations where the patient is never seen again in the 
data. This is broken down by year between 2006 and 2016 
in all databases.
The trends in Fig. 3 are as expected and provide face 
validity of the DEAD model. As CCAE is a database for 
employed patients aged 65  years or younger and their 
dependents, these patients are less likely to stop being 
observed in the database due to death, with more probable 
causes being changing insurance provider or job. Alterna-
tively, the MDCR contains an older patient population, thus 
Fig. 1  Scatter plot of variable 
means for people with death 
recorded within 61 days of the 
end of observation (y axis) vs. 
people without death recorded 
within 61 days of the end of 
observation (x axis). Green 
points correspond to variables 
included in the trained model 
and blue dots are variables that 
were not included in the trained 
model
Fig. 2  Receiver operating characteristic curve and calibration plots for the internal validation
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we would expect to see a higher percentage of patients leav-
ing the database due to death. The imputation rate trend 
seen in Optum DOD (the imputation rate is initially low 
but increases until 2013 where it seems to stabilize) also 
makes sense as we know in 2013 onwards it was not man-
datory for states to report deaths, thus not all deaths are 
likely to be recorded after 2013 and therefore the model 
will need to impute more. In CCAE/MDCD and MDCR, 
the imputation rate appears to be fairly stable over time, this 
is because these datasets only contain deaths at discharge, 
thus the deaths outside of the hospital will be identified by 
the DEAD model.
4  Discussion
4.1  Interpretation
The discriminative ability of the DEAD model was excellent 
in obtaining an internal AUC of 0.986 and external AUCs 
between 0.951 and 0.995, indicating the model can distin-
guish between end of observation due to death and end of 
observation due to non-death reasons. As the death records 
are incomplete in the other US claims databases, the external 
validation used death at discharge or non-death cases, but 
this may result in an optimistic AUC.
The results show the model is also well calibrated on the 
development dataset. It is difficult to access calibration on 
the external validation datasets because of these datasets 
being constructed of definitive death and non-deaths, thus 
extreme predictions (close to 1 or 0) may be more common. 
To determine whether the model needs to be recalibrated 
on new datasets, it will be useful to validate the model on 
another dataset that has death well recorded.
The most predictive variables were age, hospital dis-
charge records (indicating an inpatient visit), and cardio-
vascular- or cancer-related diagnoses. These variables are 
known to be linked to death and are therefore expected. The 
month that the end of observation occurred (e.g., Decem-
ber vs. January) was also informative in predicting death. 
This may be oiwng to insurance policies often ending at 
the same time, thus a certain end of observation month may 
indicate non-death and therefore decrease the risk of the end 
of observation being due to death.
Table 2  Results at various prediction threshold cut-offs that can be 
used to select the threshold used by any future epidemiology study 
when selecting an end of observations due to death
Finding people who are dead …
Prediction 
threshold
Sensitiv-
ity of 
death
Specific-
ity of 
death
Positive pre-
dictive value 
of death
Proportion of 
target popula-
tion
If you choose by prediction threshold to be greater than …
0.9 26.170 99.901 86.898 0.007
0.5 61.895 99.474 74.754 0.020
0.1 90.282 98.149 55.095 0.040
If you choose by sensitivity …
0.666 50 99.676 79.549 0.015
0.1046 90 98.184 55.489 0.040
0.0019 99 69.321 7.510 0.324
If you choose by specificity…
0.253 78.608 99 66.515 0.029
0.905 25.599 99.9 87.174 0.007
0.990 7.207 99.99 95.054 0.002
Table 3  Results at various 
prediction threshold cut-offs 
that can be used to select the 
threshold used by any future 
epidemiology study when 
selecting the non-death end of 
observations
Finding people who are still alive….
Prediction threshold Sensitivity of alive Specificity of alive Positive predic-
tive value of 
alive
Proportion of 
target popula-
tion
If you choose by prediction threshold less than …
0.5 99.474 61.895 99.046 0.980
0.1 98.149 90.282 99.752 0.960
0.01 91.351 97.196 99.923 0.892
If you choose by sensitivity …
0.00103 50 99.658 99.983 0.488
0.0085 90 97.375 99.927 0.879
0.252 99 78.624 99.460 0.971
If you choose by specificity …
0.104 98.177 90 99.747 0.960
0.00196 70.264 99 99.964 0.686
0.00055 34.636 99.9 99.993 0.338
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4.2  Implications
The results showed that developing a model using a claims 
dataset with complete death records for identifying which 
end of observations were due to death or non-death reasons 
resulted in a good discriminative ability and this model was 
validated across several datasets and showed a consistently 
high externally validated AUC. This suggests the model 
could be a useful tool to identify death in US claims data and 
this would be useful for epidemiology studies. The suitable 
risk threshold chosen to classify end of observations into 
death vs. non-death would depend on the study. Studies that 
want to be confident that the end of observation predicted to 
be death would truly be dead should use a higher threshold 
such as 0.9, whereas studies that want to capture as many 
deaths as possible and are less interested in the false-positive 
rate should use a lower threshold such as 0.10. We provided 
Table 2 that can guide the user into a suitable threshold to 
use. For example, if the user wanted a group of patients very 
likely to be dead then he/she can pick all patients with a 
DEAD risk score greater than 0.9, whereas if he/she wanted 
a group of patients very likely to be alive, then he/she could 
select all patients with a DEAD risk score less than 0.001.
The model can be used to impute death by applying it 
at the point in time when a patient stops being observed 
in a database (the end of observation date). If a patient is 
assigned a sufficiently high risk value by DEAD, then they 
can be considered to have died on the date their observation 
ended. If you want to identify the majority of true deaths, 
then a risk threshold of 0.1046 would identify 90% of all 
deaths (anyone who has a DEAD risk of 0.1046 or more 
on the date they leave the databases are considered to have 
died on the date they leave the database and otherwise they 
are considered to still be alive). If you want to identify a 
set of patients likely to be dead, then a risk threshold of 0.9 
would identify approximately 26% of all deaths with a high 
specificity and PPV of 86.9%.
At prediction thresholds > 0.9 or specificity thresh-
olds > 0.999, the performance of this death phenotype com-
pares favorably with phenotypes developed for other con-
ditions. For example, Rubbo et al. performed a systematic 
review of acute myocardial infarction phenotype validations, 
which estimated PPVs between 88 and 92% [11]. Kumamaru 
et al. estimated a 90% PPV for ischemic stroke [12]. Many 
published definitions only present PPV with sensitivity an 
unknown. In addition, our definition is a model rather than a 
set of codes, thus the user can pick the operating character-
istic that best suits the application (e.g., high PPV and low 
sensitivity or high sensitivity and lower PPV).
Fig. 3  Percentage of the final end of observation per year that are 
due to death or imputed as due to death by the DEAD model for 
each databases across the years 2006–16. CCAE IBM  MarketScan® 
Commercial Database, MDCD IBM  MarketScan® Multi-State Med-
icaid Database, MDCR IBM  MarketScan® Medicare Supplemental 
Database, OPTUM Optum© De-Identified  Clinformatics® Data Mart 
Database
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4.3  Limitations
The main limitation of this study is that death is not well 
recorded in the datasets used to validate the model (the vali-
dation data only have death at discharge). This is a predica-
ment, as the lack of complete death records in observational 
data prompted this research but also makes validation diffi-
cult. The results show the DEAD model appears to transport 
to other US claims datasets. However, it would be benefi-
cial to validate it on more datasets, including as non-US 
and non-claims data, to gain additional confidence into the 
transportability. As the model has been developed on the 
Observational Medical Outcome Partnership common data 
model, it is possible in future work to design a network study 
to share the model with other researchers who may have 
complete death records.
Because the model training was performed on data prior 
to 2013 and no complete validation data were available 
in later years, we cannot assure the external validity, and 
changes in healthcare practice and data coding strategies 
(such as the International Classification of Diseases, Ninth 
Revision, Clinical Modification to the International Classi-
fication of Diseases, Tenth Revision, Clinical Modification 
transition) could impact its performance. Additionally, the 
requirement of looking for a death record within 61 days 
of an end of observation to classify it as being due to death 
may result in some misclassification where an end of obser-
vation is incorrectly labeled as not being due to death (e.g., 
the death record date was more than 61 days before/after 
the observation end). This was a trade-off between using a 
longer time period around an end of observation that would 
increase the chance of misclassification where an end of 
observation not due to death is incorrectly labeled as being 
due to death.
5  Conclusion
In this article, we developed the DEAD model that deter-
mines whether an end of observation in US claims data is 
due to death. The model was developed using a US claims 
database with complete death records, thus the target popu-
lation was individuals with an end of observation and the 
outcome was an end of observation due to death. The model 
obtained a discrimination performance AUC of 0.986 on the 
internal validation and AUCs ranging from 0.951 to 0.995 
on the external validation. The internal validation sug-
gested the model was well calibrated but further application 
of the model to more datasets with complete death records 
is required to access the external calibration of the model. 
Mortality is often an outcome of interest in epidemiological 
studies but is often poorly recorded in US claims data. The 
model developed in this article can now be implemented to 
impute death in US claims data at various sensitivities or 
specificities. In the future, it would be useful to extend the 
external validation across the OHDSI network and outside 
the OHDSI network, so the performance can also be evalu-
ated on non-US or non-claims data.
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